National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024
36Supplies of doses of chemotherapy drugs by approved pharmacists and approved medical practitioners
Start here
Get a plain-English read of 36
Turn the raw legal text into a practical explanation grounded in National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024.
36 Supplies of doses of chemotherapy drugs by approved pharmacists and approved medical practitioners
(1) Subject to section 40 of this instrument, this section sets out amounts that an approved pharmacist or approved medical practitioner must or may charge an eligible patient for a special arrangement supply of a dose of a chemotherapy drug.
Note: Section 40 of this instrument applies to an original special arrangement supply of a dose of a chemotherapy drug if the supply is made to a CTG registered patient by a CTG supplier.
Patient co‑payment must be charged for original supply only (2) For an original supply of a dose, the approved pharmacist or approved medical practitioner must charge the patient an amount that is equivalent to the amount that may be charged under subsection 87(2) of the Act for the supply of a pharmaceutical benefit to the patient.
Note: This is a single amount for supply of the dose, not a separate amount for supply of each chemotherapy pharmaceutical benefit used to make the dose.
(3) No amount may be charged under subsection (2) for a repeated supply. (3A) In addition, if the supply is made to an eligible patient who is a CTG registered patient by a CTG supplier, no amount may be charged under subsections 11(1) to (3) of the CTG Special Arrangement for a repeated supply.
Note: See section 40 of this instrument in relation to the application of the CTG Special Arrangement.
Special patient contribution for original or repeated supply (4) If a determination under subsection 85B(3) of the Act is in force in relation to a chemotherapy pharmaceutical benefit used to make the dose: (a) the approved pharmacist or approved medical practitioner may charge a special patient contribution in accordance with the Act for supply of the benefit; and (b) subsection 85B(5) of the Act applies as if a reference to the Commonwealth price for a quantity or number of units of a listed brand of a pharmaceutical item were a reference to the dispensed price for a dose of a chemotherapy drug made using a quantity or number of units of a listed brand of a pharmaceutical item.